Annual Meeting Helps Impact Ability to Communicate | Helps Understand Knowledge Gaps

Annual Meeting Helps Impact Ability to Communicate | Helps Understand Knowledge Gaps

Annual-Meeting

1 year
91 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Annual Meeting Helps Impact Ability to Communicate | Helps Understand Knowledge Gaps at Annual Meeting 2018
Up Next Autoplay
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
10 Views
Cancer-News 4 weeks
EV-103 Phase I Trial Presented at #ESMO19
EV-103 Phase I Trial Presented at #ESMO19
Category: Bladder Cancer
20 Views
Cancer-News 4 weeks
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Category: Bladder Cancer
28 Views
Cancer-News 1 month
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Category: Bladder Cancer
21 Views
Cancer-News 2 months
Strategies for Treating 2nd Line RCC Patients
Strategies for Treating 2nd Line RCC Patients
Category: Bladder Cancer
53 Views
obr 4 months
Treating Newly Diagnosed RCC Patients
Treating Newly Diagnosed RCC Patients
Category: Bladder Cancer
52 Views
obr 4 months
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Category: Bladder Cancer
110 Views
obr 4 months
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Category: Bladder Cancer
49 Views
obr 4 months
TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
Category: Bladder Cancer
175 Views
Annual-Meeting 5 months
The Broad Implications of The SAUL Study
The Broad Implications of The SAUL Study
Category: Bladder Cancer
208 Views
Annual-Meeting 5 months